Philippe Corcia is Professor of Neurology and responsible for the ALS Center of the CHU of Tours. This is the only center of the Loire Valley area: in this center, more than 90 new cases are diagnosed every year and the cohort of ALS patients currently exceeds 240 patients. Philippe Corcia is member of the French Neurological Society (SFN), of the European Academy of Neurology and of the panel of the ALS of fronto temporal dementia. He is also member of the ENCALS and TRICALS board and of the Editorial Board of the ALS FTD Journal. He is involved in the scientific committee of the French ALS network (FILSLAN). He was the principal investigator of several clinical trials over the last five years. His field of research is mainly focused on genetic factors and metabolomics in ALS. He is member of the Inserm Unit U1253 iBrain. He signed or co-signed more than 200 publications which mainly dealt with ALS or motor neuron disorders.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.